Psilocybin
→Depressive symptoms

1

15

2

↑1

↓15

—2

Evidence suggests Psilocybin maydecreaseDepressive symptoms.

9 studies (18 claims)

Moderate consensus

Typical effective dose 25 (25–25) mgacross 1 dosed study

Study Claims

18 of 18

Intervention	Direction	Endpoint	Type	Population	Dosage	Title
two-dose psilocybin administration	Decreases - yielding more pronounced and lasting effects	depressive symptoms severity	Human	—	Single-dose and two-dose psilocybin treatments (specific amounts not provided).	Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials.cited 3×
two-dose psilocybin treatments	Decreases - significantly reduced	depressive symptoms severity	Human	patients with a primary diagnosis of MDD or TRD	Single-dose and two-dose psilocybin treatments (specific amounts not provided).	Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials.cited 3×
single-dose psilocybin treatments	Decreases - significantly reduced	depressive symptoms severity	Human	patients with a primary diagnosis of MDD or TRD	Single-dose and two-dose psilocybin treatments (specific amounts not provided).	Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials.cited 3×
Psilocybin	Decreases - is highly effective in reducing	depressive symptoms severity	Human	patients with primary MDD or TRD	Single-dose and two-dose psilocybin treatments (specific amounts not provided).	Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials.cited 3×
high dose psilocybin	Decreases - showed better responses than those treated with placebo	depressive symptoms	Human	patients	Not specified for Ayahuasca.	Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.cited 4×
Group psilocybin-assisted therapy plus MBSR	Decreases - associated with clinically significant improvement	depressive symptoms	Human	physicians and nurses	8-week MBSR curriculum (frequency not specified) plus a single 25mg psilocybin dose in the combined group.	Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial.
psilocybin-assisted therapy	Decreases - has shown promising efficacy	clinical depressive symptoms	Human	—	Not specified	The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis.cited 2×
psilocybin-assisted therapy	No effect - improvement was not associated with	depressive symptoms	Human	adult patients receiving psilocybin-assisted therapy	Not specified	The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis.cited 2×
psilocybin-assisted therapy	Decreases - pooled standard mean difference	depressive symptoms measured by 17-Item Hamilton Depression Rating Scale	Human	adult patients with clinically diagnosed depression	Not specified	The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis.cited 2×
psilocybin	Decreases - were associated with large effect sizes	depressive symptoms	Human	adult patients with depressive symptoms	Not available	The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis.
psilocybin	No effect - were not statistically significant	depressive symptoms	Human	adult patients with depressive symptoms	Not available	The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis.
psilocybin	Decreases - showed a large effect size	depressive symptoms	Human	adult patients with depressive symptoms	Not available	The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis.
psilocybin	Decreases - showed a large effect size	depressive symptoms	Human	adult patients with depressive symptoms	Not available	The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis.
psilocybin	Increases - was effective in improving	depressive symptoms	Human	patients with MDD	Not specified in the abstract.	Psilocybin for major depressive disorder: a systematic review of randomized controlled studies.cited 3×
psilocybin	Decreases - demonstrate large depressive symptom improvements	depressive symptoms	Human	clinical trials	Not provided.	Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action.
psilocybin	Decreases - significantly decreased	depressive symptoms	Human	participants with severe treatment-resistant depression	25 mg (single dose).	Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial.cited 3×
psilocybin	Decreases - significantly decreased	depressive symptoms	Human	participants with severe treatment-resistant depression	25 mg (single dose).	Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial.cited 3×
psilocybin	Decreases - causes a significant reduction in	depressive symptoms	Human	participants in larger Phase II trials	Single 25 mg dose mentioned in the largest clinical trial.	Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.cited 7×